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Abstract
Background: Pulmonary tumor thrombotic microangiopathy (PTTM), a rare complication of advanced cancer, is
histologically characterized by tumor embolisms and fibrocellular intimal proliferation of small pulmonary arteries
and arterioles. PTTM usually has an extremely poor prognosis, and antemortem diagnosis is very difficult.
Case presentation: A 65-year-old woman with a 5-year history of clinical stage IIA (T2N0M0) invasive ductal carcinoma
of the left breast was hospitalized for worsening shortness of breath, hemoptysis, and cough since 2 months. She had
previously received neoadjuvant chemotherapy and left mastectomy. Because the cancer cells were positive for human
epidermal growth factor receptor 2 (HER2), four cycles of trastuzumab had been administered as adjuvant chemotherapy.
On admission, chest computed tomography (CT) showed peripheral consolidations in both the lower lobes
and a mediastinal mass. Specimens obtained on video-assisted thoracoscopic surgical biopsy revealed tumor
cell embolism, intimal fibrocellular proliferation of small arteries, fibrin thrombi, recanalization, and infarction in
the left lower lobe, as well as metastasis to the mediastinal pleura. Immunohistochemical staining of the
tumor cells revealed positivity for HER2, and a diagnosis of recurrent breast cancer with PTTM was made.
Four cycles of trastuzumab resulted in rapid improvement of her symptoms and CT findings of peripheral
consolidations and the mediastinal mass.
Conclusion: An antemortem diagnosis of PTTM was made in a patient with HER2-positive recurrent breast cancer.
Trastuzumab was effective for not only breast cancer but also PTTM.
Keywords: Pulmonary tumor thrombotic microangiopathy, Breast cancer, Tumor embolism, Trastuzumab, Human
epidermal growth factor receptor 2
Abbreviations: CT, Computed tomography; FDG, 18F-fluorodeoxyglucose; HER2, Human epidermal growth factor
receptor 2; PTTM, Pulmonary tumor thrombotic microangiopathy; VATS, Video-assisted thoracoscopic surgery
Background
Pulmonary tumor thrombotic microangiopathy
(PTTM) is a rare complication of advanced cancer; it is
histologically characterized by tumor embolisms and
fibrocellular intimal proliferation of small pulmonary
arteries and arterioles [1]. PTTM causes rapidly pro-
gressive pulmonary hypertension, right heart failure,
and death in a few days. It is usually diagnosed on
autopsy and is rarely diagnosed antemortem [2–8]. The
most frequent underlying malignancy is gastric adeno-
carcinoma, while breast cancer is an infrequent cause
of PTTM [1, 9, 10]. Herein, we report a patient with
human epidermal growth factor receptor 2 (HER2)-
positive recurrent breast cancer with accompanying
PTTM without pulmonary hypertension; the diagnosis
was made antemortem, and the patient responded well
to trastuzumab therapy.
* Correspondence: takahashiyui413@gmail.com
1Department of Respiratory Medicine, Respiratory Center, Toranomon Hspital,
2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Takahashi et al. BMC Cancer  (2016) 16:666 
DOI 10.1186/s12885-016-2721-3
Case presentation
A 65-year-old woman with a 5-year history of clinical
stage IIA (T2N0M0) invasive ductal carcinoma of the
left breast was hospitalized for worsening shortness of
breath, hemoptysis, and cough since 2 months. Her
breast carcinoma was 32 mm in diameter at diagnosis,
with a histologic grade of 3 and nuclear grade of 3. Im-
munostaining for the estrogen receptor and progester-
one receptor revealed negativity for both, but the tumor
cells were positive for HER2. The patient had received
neoadjuvant chemotherapy with four cycles of epirubicin
and cyclophosphamide, followed by four cycles of trastu-
zumab and paclitaxel. A left mastectomy had been per-
formed, and the surgical specimen showed no residual
cancer. After the operation, four cycles of trastuzumab
had been administered as adjuvant chemotherapy; how-
ever, trastuzumab had been discontinued because of
heart failure. Echocardiography showed diffuse and
moderate impairment of left ventricular contraction and
a decrease in ejection fraction from 65.8 % to 36 %.
Seven months after stopping trastuzumab administra-
tion, a repeat echocardiography revealed that her ejec-
tion fraction had recovered. Since then, she had been
followed-up without treatment for breast carcinoma
until this readmission.
On admission, the patient showed normal auscultation
findings. A chest radiograph showed faint infiltrates at
the base of both the lungs. Arterial blood gas analysis
using room air indicated minimal hypoxemia: pH, 7.42;
PaCO2, 42 mmHg; and PaO2, 78 mmHg. D-dimer levels
were slightly increased to 1.2 μg/mL (normal, <1.0 μg/
mL). Serum levels of carcinoembryonic antigen and
HER2 were elevated to 57.0 μg/L (normal, 0.8–4.8 μg/L)
and 64.9 ng/mL (normal, <15.2 ng/mL), respectively.
Contrast-enhanced computed tomography (CT) scans
revealed peripheral consolidation with ground-glass
opacity in both the lower lobes and a heterogeneous
mediastinal mass (Fig. 1). 18F-fluorodeoxyglucose
(FDG)-positron emission tomography demonstrated
increased FDG uptake in the peripheral consolidation
and the mass. Echocardiography revealed normal con-
tractions without any finding suggestive of pulmonary
hypertension. Because transbronchial lung biopsy did
not lead to any diagnosis, video-assisted thoracoscopic
surgery (VATS) lung biopsy was performed. The surgical
specimens of the peripheral area of the left lower lobe
and the mediastinal mass revealed tumor cell embolism,
intimal fibrocellular proliferation of small arteries, fibrin
thrombi, recanalization, and infarction in the left lower
lobe, as well as metastasis to the mediastinal pleura
(Fig. 2). Immunohistochemical staining of tumor cells
revealed positivity for mammaglobin, gross cystic disease
fluid protein 15, HER2 (3+), and vascular endothelial
growth factor. Accordingly, a diagnosis of recurrent
breast cancer with PTTM was made.
Retreatment with trastuzumab therapy rapidly im-
proved the symptoms and CT findings of peripheral con-
solidation and the mass, resulting in partial remission
(Fig. 3). After four cycles of trastuzumab therapy, it was
stopped owing to heart failure. The patient visited an-
other hospital and is alive more than 2 years after the
diagnosis of PTTM.
Discussion
We report a patient with recurrent breast cancer to the
left lung accompanied by PTTM, which was diagnosed
antemortem. The onset was subacute, and respiratory
failure was absent. Although transbronchial lung biopsy
could not help in making a diagnosis, the results ob-
tained with VATS lung biopsy led to the diagnosis.
Treatment with trastuzumab, a humanized monoclonal
antibody that targets the extracellular domain of HER2,
rapidly resolved the patient’s symptoms and CT findings.
Because PTTM is usually diagnosed postmortem, the
clinical manifestations are not fully understood. Unlike
in the present patient, the prognosis is known to be ex-
tremely poor. The incidence of PTTM is 0.9–3.3 % in
autopsy patients with carcinoma, and the most common
Fig. 1 Chest computed tomography scans on admission. a, b Irregular shaped peripheral consolidations in both the lower lobes. c A heterogeneously
enhanced mediastinal mass
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origin was gastric carcinoma, followed by lung and
breast carcinoma [1, 9, 10]. The proposed mechanism of
PTTM is that tumor cells activate the coagulation sys-
tems and release inflammatory mediators and growth
factors including vascular endothelial growth factor,
resulting in thrombosis, fibrocellular intimal prolifera-
tion, and luminal stenosis [5]. Elevated serum levels of
D-dimer and fibrin degradation products have been
reported [10]. Patients with PTTM frequently develop
severe pulmonary hypertension and disseminated intra-
vascular coagulation, but our patient did not have either.
PTTM differs from tumor emboli in terms of accom-
panying activation of the coagulation system and intimal
proliferation in small arteries [1]. Clinically, patients with
PTTM usually show rapid worsening of respiratory func-
tion, with or without pulmonary hypertension. Unlike
tumor emboli, the proximal pulmonary arteries do not
show defects on contrast-enhanced CT scans of patients
with PTTM.
In the present patient, a prominent CT finding was
the peripheral consolidation in both the lower lobes,
which was pathologically correlated with infarction.
After breast cancer treatment, chest CT can show
abnormalities due to various causes including radi-
ation pneumonitis, chemotherapy-induced interstitial
changes, pulmonary infection under immunosup-
pressed condition, cancer related thromboembolic
events including PTTM, and pulmonary metastasis
[11]. Among them, CT findings of PTTM include
consolidations, ground-glass opacities, small nodules,
and tree-in-bud appearance [2, 5, 7, 10, 12]. We
should consider breast cancer recurrence with PTTM
Fig. 2 Histopathological findings of the surgical specimens. a Widespread infarction (hematoxylin and eosin staining, ×2); b Tumor fibrin embolism
in a pulmonary arteriole (hematoxylin and eosin staining, ×10); c Fibrocellular intimal proliferation (elastic van Gieson staining, ×10); d Tumor cells (at
increased magnification, hematoxylin and eosin staining, ×60); and e Tumor cells demonstrating HER2 positivity (immunohistochemical staining, ×60)
Fig. 3 Chest computed tomography scans after trastuzumab therapy showing improvements of (a) consolidations in both the lower lobes and
(b) the mediastinal mass.
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as a differential diagnosis if a patient presents with
respiratory symptoms and abnormalities on chest CT
images, after breast cancer treatment.
To our knowledge, only 10 patients have been suc-
cessfully diagnosed with PTTM antemortem (Table 1)
[2–8, 12, 13]. The primary site was the upper gastro-
intestinal tract (n = 4), breasts (n = 3), unknown (n =
2), and lungs (n = 1). The diagnostic methods for
PTTM were transbronchial lung biopsy in five pa-
tients and VATS in three. Pulmonary hypertension
was detected in five patients. All but one patient received
treatment with anti-cancer drug and seven patients sur-
vived for more than 3 months. Among them, only the
present patient received a molecular-targeted drug trastu-
zumab that acts against known molecular abnormalities.
Trastuzumab therapy was effective for not only breast
cancer but also PTTM.
Although von Herbay et al. first reported PTTM [1],
almost all previous reports have been from Japan. Al-
though we do not know the exact reason for this, there
are several possibilities. First, the prevalence of gastric
cancer is high in Japan. Second, Japanese patients can
access hospital care easily owing to a national insurance
system. Lastly, teaching hospitals, including ours, under-
stand the importance of autopsy, and we try to perform
autopsy as often as possible.
Conclusions
PTTM should be included in the differential diagnosis
when breast cancer patients exhibit progressive respira-
tory symptoms with lung infiltrations without pulmon-
ary infection or heart failure. When tumor cells are
positive for an oncogenic driver such as HER2,
genotype-directed therapy seems promising for the treat-
ment of both cancer and PTTM.
Acknowledgements
We thank Dr. Toshimi Takano (Department of Medical Oncology, Toranomon
Hospital) for his advice regarding the treatment of breast cancer.
Funding
The research has no sources of funding.
Availability of data and material
Data are available on request due to privacy.
Authors’ contributions
YT is the first and corresponding author of the manuscript. HU, SM, SH, HT,
AM, and NM collected the patient’s data and provided figures. HU and TF
performed pathologic evaluation. AK evaluated CT findings. KK gave final
approval of the version to be published. The final version of the manuscript
was seen and approved by all authors.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
The patient provided written informed consent for publication of this case
report and the associated images.
Table 1 Previously reported antemortem diagnoses of PTTM
Year Author Primary site Diagnostic method
of PTTM
CT findings PH Treatment Survival time
2007 Miyano et al. [5] Stomach VATS Multiple tiny nodules - S-1 + dexamethasone
+ warfarin, aspirin
9 months
2008 Noguchi et al. [12] Stomach TBLB Tiny nodules + No treatment 10 days
2008 Uruga et al. [8] Lung CT guided biopsy Consolidation, ground glass
attenuation
- Carboplatin, paclitaxel 7 months






2011 Ueda et al. [7] Esophagus TBLB Multiple bilateral diffuse interstitial
infiltrative shadows
+ Fluorouracil, nedaplatin 9 days
2012 Kayatani et al. [3] Unknown VATS Centrilobular ultrafine granular
shadows
- S-1, cisplatin 15 months
2013 Ogawa et al. [6] Gastroduodenum TBLB A nodular shadow and septal thicken






2013 Kitamura et al. [4] Breast TBLB Ground glass opacities around the
bronchovascular bundles
- Irinotecan + warfarin 3 months
2014 Higo et al. [13] Breast Pulmonary wedge
aspiration
Mosaic pattern + Bosentan, tadalafil
+ imatinib, bevacizumab +
S-1
12 months
2015 Takahashi et al.
(present case)
Breast VATS Peripheral consolidation in both
lower lobes
- Trastuzumab 32 months
PTTM Pulmonary tumor thrombotic microangiopathy, PH pulmonary hypertension, TBLB transbronchial lung biopsy, VATS Video-assisted thoracoscopic surgery, S-1
tegafur, gimeracil oteracil potassium
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